The graph depicts Pfizer's top 10 products based on revenue in 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's top product was Eliquis. COVID-19 vaccine Comirnaty, on the other hand, showed another dramatic decline in sales from 11.2 billion U.S. dollars in 2023 to 5.4 billion dollars. Pfizer's top productsPfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2024, Pfizer generated a total revenue of 63.6 billion U.S. dollars worldwide, with oncology products accumulating some 15.6 billion U.S. dollars.Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around 3.3 and five billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of 12.9 billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under two billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at 63.6 billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than 200 research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Keytruda is projected to stay the top-ranked drug worldwide based on sales in 2025, with some 31 billion U.S. dollars. This statistic displays the expected top drugs in 2025 based on sales projections as of December 2024. It has to be mentioned that Novo Nordisk's brands Ozempic and Wegovy are, in fact, the same drug (generic name semaglutide), where only dosage and dose form define if it is used for diabetes or weight loss. It is very similar in the case of Eli Lilly's Mounjaro and Zepbound which are basically one and the same drug (generic name tirzepatide). Oncology's dominance in pharmaceutical revenues Cancer treatments are becoming increasingly crucial in the pharmaceutical landscape. Keytruda's projected sales for 2025 underscore this trend, while the drug's revenue increased by more than four billion dollars between 2023 and 2024. This growth is part of a larger pattern in global oncology spending, which exceeded 250 billion U.S. dollars globally in 2024, almost doubling from five years earlier. The substantial investment in cancer treatments is likely to continue, with major pharmaceutical companies like Johnson & Johnson, AstraZeneca, and Merck expected to be the oncology market leaders by 2030. Market dynamics and company performance Merck & Co. has seen its overall revenue increase to 64 billion in 2024, driven largely by its oncology franchise. The company's commitment to innovation is evident in its record-high R&D spending in 2023. This focus on research and development is crucial for maintaining competitiveness in the industry, as demonstrated by the changing rankings of top-selling drugs. For instance, AbbVie's Humira, once a blockbuster, dropped out of the top 10 best-selling drugs in 2024 due to patent expiration, highlighting the constant need for pharmaceutical companies to innovate and develop new products to maintain their market position.

Lipitor, which was introduced by Pfizer back in 1997, is expected to be the drug with the third highest lifetime sales at the end of 2028. As of end-2022, the cholesterol-lowering drug aggregated lifetime sales of 172 billion U.S. dollars, which is expected to increase for some additional six billion dollars until 2028.

The global Top 10 Cancer Drugs Market was valued at $79.85 billion in 2022, and is projected to reach $149.52 billion by 2030, growing at a CAGR of 9.38%.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data was reported at 1,753,000.000 USD th in Jun 2018. This records an increase from the previous number of 812,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,980,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 3,433,000.000 USD th in Dec 2017 and a record low of 707,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Pfizer held nine percent of the world's pharmaceutical drug market in 2022. The global market for prescribed medicines is expected to be led by U.S. companies, accompanied by Swiss pharma giants Roche and Novartis.

Prescription and over-the-counter drugs The total global prescription drug market – including generic and orphan drugs – was estimated at 1.12 trillion U.S. dollars for 2022. Especially the orphan drug market is a major driver and expected to more than double its revenues in only seven years between 2019 and 2026. Prescribed (Rx) drugs are drugs which can be only obtained with a physician’s prescription. In contrast to these, there is the group of so called over-the-counter (OTC) drugs which can be purchased directly without a prescription. Typical examples for OTC drugs are lower-dosed pain killers like aspirin or ibuprofen.

Pfizer as global leader New York City-based Pfizer has been among the largest pharmaceutical companies for many years based on combined prescribed and OTC drug revenue. Today, the company is totally focused on human medicine, divided into four major segments: Primary Care, Specialty Care, Oncology, and Pfizer Centreone. Pfizer also had a significant animal health division until 2013. The company generates about half of its revenues inside the United States. Among Pfizer’s perhaps most famous drug ever produced is the potency pill Viagra.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data was reported at 2,835,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,314,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data is updated quarterly, averaging 3,304,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 5,806,000.000 USD th in Dec 2014 and a record low of 1,174,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Pfizer Inc. (Pfizer) discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US. Read More

Pfizer is a multinational pharmaceutical company that is headquartered in New York City, New York. Pfizer’s expenditures on research and development (R&D) have been variable in recent history. In 2024, Pfizer spent some 10.8 billion U.S. dollars on R&D efforts. Pfizer’s company profile Pfizer is one of the world’s largest pharmaceutical companies. The company has pharmaceuticals in a number of therapeutic areas, including oncology, endocrinology, cardiology, and neurology. The Prevnar family is one of Pfizer’s top revenue-generating drugs. Prevnar is a vaccine used to prevent pneumococcal pneumonia. The company has undergone several mergers and acquisitions in recent history. In 1999, Pfizer and Warner-Lambert joined, forming one of the most valuable pharmaceutical mergers of all time. Pharmaceutical research and development Pharmaceutical R&D is crucial for finding and creating new drug compounds and agents that have the potential to save lives (or improve medical symptoms). Pharmaceutical R&D in the U.S. has become a booming industry and spending is increasing year-over-year. The number of federally registered clinical trials in the U.S. has been increasing significantly recently as well. One area of health that has been significantly impacted by R&D investment is oncology.

United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data was reported at 2,340,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,591,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data is updated quarterly, averaging 2,277,000.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 4,442,000.000 USD th in Dec 2015 and a record low of 778,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: International data was reported at 10,238,000.000 USD th in Sep 2018. This records an increase from the previous number of 6,891,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International data is updated quarterly, averaging 8,591,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 14,836,000.000 USD th in Dec 2015 and a record low of 3,220,000.000 USD th in Mar 2017. United States US: PFE: Revenue (External): Essential Health Product: International data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: US data was reported at 4,859,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,379,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: US data is updated quarterly, averaging 4,849,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 9,596,000.000 USD th in Dec 2016 and a record low of 1,731,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Sales from the United States contributed more than 38 billion U.S. dollars towards Pfizer's total revenue of around 63.6 billion U.S. dollars in 2023. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to company revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.

United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data was reported at 2,394,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,158,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data is updated quarterly, averaging 2,571,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 4,381,000.000 USD th in Dec 2017 and a record low of 872,000.000 USD th in Mar 2016. United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

[Keywords] Market include AbbVie Inc., Allergan plc., GlaxoSmithKline plc., Keryx Biopharmaceuticals Inc., Pfizer Inc.

Subscribers can find out export and import data of 23 countries by HS code or product’s name. This demo is helpful for market analysis.

Find details of Pharmacia And Upjohn C O Pfizer Romence Buyer/importer data in US (United States) with product description, price, shipment date, quantity, imported products list, major us ports name, overseas suppliers/exporters name etc. at sear.co.in.

This statistic displays the leading 10 global vaccine products based on their revenues worldwide in 2023. Pfizer's COVID-19 vaccine Comirnaty generated nearly 11.2 billion U.S. dollars in revenues in that year. Top vaccine products Vaccines act as a preventive measure to improve immunity to certain diseases. Often, vaccines are created from a weakened or killed form of a microbe which allows the immune system to react and create a record of it, so that in the future, it can easily recognize these microorganisms. Vaccine use can easily help to prevent contraction of certain viruses such as influenza. However, some countries may not have easy access to vaccinations. The global vaccination market is projected to reach around 95 billion U.S. dollars in 2029. In 2023, Comirnaty and Gardasil were the top revenue generating vaccines in the world, generating 11.2 billion and 68.9 billion U.S. dollars, respectively. Comirnaty is marketed by Pfizer and BioNTech, while Gardasil is marketed by Merck & Co.

LISTOS_Ground_BronxPfizer_Data is the Long Island Sound Tropospheric Ozone Study (LISTOS) ground site data collected at the Bronx Pfizer ground site during the LISTOS field campaign. This product is a result of a joint effort across multiple agencies, including NASA, NOAA, the EPA Northeast States for Coordinated Air Use Management (NESCAUM), Maine Department of Environmental Protection, New Jersey Department of Environmental Protection, New York State Department of Environmental Conservation and several research groups at universities. Data collection is complete. The New York City (NYC) metropolitan area (comprised of portions of New Jersey, New York, and Connecticut in and around NYC) is home to over 20 million people, but also millions of people living downwind in neighboring states. This area continues to persistently have challenges meeting past and recently revised federal health-based air quality standards for ground-level ozone, which impacts the health and well-being of residents living in the area. A unique feature of this chronic ozone problem is the pollution transported in a northeast direction out of NYC over Long Island Sound. The relatively cool waters of Long Island Sound confine the pollutants in a shallow and stable marine boundary layer. Afternoon heating over coastal land creates a sea breeze that carries the air pollution inland from the confined marine layer, resulting in high ozone concentrations in Connecticut and, at times, farther east into Rhode Island and Massachusetts. To investigate the evolving nature of ozone formation and transport in the NYC region and downwind, Northeast States for Coordinated Air Use Management (NESCAUM) launched the Long Island Sound Tropospheric Ozone Study (LISTOS). LISTOS was a multi-agency collaborative study focusing on Long Island Sound and the surrounding coastlines that continually suffer from poor air quality exacerbated by land/water circulation. The primary measurement observations took place between June-September 2018 and include in-situ and remote sensing instrumentation that were integrated aboard three aircraft, a network of ground sites, mobile vehicles, boat measurements, and ozonesondes. The goal of LISTOS was to improve the understanding of ozone chemistry and sea breeze transported pollution over Long Island Sound and its coastlines. LISTOS also provided NASA the opportunity to test air quality remote sensing retrievals with the use of its airborne simulators (GEOstationary Coastal and Air Pollution Events (GEO-CAPE) Airborne Simulator (GCAS), and Geostationary Trace gas and Aerosol Sensory Optimization (GeoTASO)) for the preparation of the Tropospheric Emissions; Monitoring of Pollution (TEMPO) observations for monitoring air quality from space. LISTOS also helped collaborators in the validation of Tropospheric Monitoring Instrument (TROPOMI) science products, with use of airborne- and ground-based measurements of ozone, NO2, and HCHO.